



Medicinal Cannabis and Chronic Pain

Module 1: Education for Clinicians

Introduction

Thompson, M. (July 22, 2013). The mysterious history of “marijuana.” NPR. Free online: <https://www.npr.org/sections/codeswitch/2013/07/14/201981025/the-mysterious-history-of-marijuana>

Section 1: The Endocannabinoid System

Bostwick, J.M. (2012). Blurred boundaries: the therapeutics and politics of medical marijuana. *Mayo Clinic Proceedings*, 87(2), 172-186. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538401>

Gaoni, Y. & Mechoulam, R. (1964). Isolation, structure and partial synthesis of an active constituent of hashish. *Journal of the American Chemical Society*, 86, 1646–7. View abstract: <http://pubs.acs.org/doi/abs/10.1021/ja01062a046>

Howlett, A.C., Breivogel, C.S., Childers, S.R., Deadwyler, S.A., Hampson, R.E., Porrino, L.J. (2004). Cannabinoid physiology and pharmacology: 30 years of progress. *Neuropharmacology*, 47 Suppl 1, 345-58. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/15464149>

Mackie, K. (2006). Cannabinoid receptors as therapeutic targets. *Annual Review of Pharmacology and Toxicology*, 46, 101-22. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/16402900>

Russo, E.B. & Hohmann, A.G. (2013). Role of cannabinoids in pain management. In: *Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches*, 181-197. View abstract: http://link.springer.com/chapter/10.1007%2F978-1-4614-1560-2_18

Wilson, R.I. & Nicoll, R.A. (2002). Endocannabinoid signaling in the brain. *Science*, 296(5568), 678-82. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/11976437>

Section 2: Cannabinoids

Attal, N., Brasseur, L., Guirimand, D., Clermond-Gnamien, S., Atlami, S., & Bouhassira, D. (2004). Are oral cannabinoids safe and effective in refractory neuropathic pain? *European Journal of Pain*, 8, 173-7. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/14987627>

Carlini, E.A., Leite, J.R., Tannhauser, M., & Berardi, A.C. (1973). Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. *Journal of Pharmacy and Pharmacology*, 25, 664-665. View abstract: <http://onlinelibrary.wiley.com/doi/10.1111/j.2042-7158.1973.tb10660.x/abstract>



Clermont-Gnamien, S., Atlani, S., Attal, N., Le Mercier, F., Guirimand, F., & Brasseur, L. (2002). Utilisation thérapeutique du delta-9-tétrahydrocannabinol (dronabinol) dans les douleurs neuropathiques réfractaires [The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain]. *La Presse Médicale*, 31(39 Pt1), 1840-5.

Cunha, J.M., Carlini, E.A., Pereira, A., Ramos, O.L., Pimentel, C., Gagliardi, R., Sanvita, W.L., Lander, N., & Mechoulam, R. (1980). Chronic administration of cannabidiol to healthy volunteers and epileptic patients. *Pharmacology*, 21(3), 175-185. View abstract: <https://www.karger.com/Article/Abstract/137430>

Evans, F.J. (1991). Cannabinoids: the separation of central from peripheral effects on a structural basis. *Planta Medica*, 57, S60–S67. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/1659702>

Federal Drug Administration. (2018). Epidiolex [prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf

GW Pharmaceuticals. (n.d.). Epidiolex: A treatment innovation. Retrieved August 5, 2020 from <https://www.epidiolex.com/about-epidiolex>

GW Pharmaceuticals. (n.d.). Sativex. Retrieved August 5, 2020 from <https://www.gwpharm.com/healthcare-professionals/sativex#>

Leite, J.R., Carlini, E.A., Lander, N., & Mechoulam, R. (1982). Anticonvulsant effects of the (-) and (+) isomers of Cannabidiol and their Dimethylheptyl homologs. *Pharmacology*, 24, 141-146. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/7071126>

McPartland, J.M. & Russo, E.B. (2001). Cannabis and cannabis extracts: greater than the sum of their parts? Co-published simultaneously in *Journal of Cannabis Therapeutics*, 1(3/4),103-132 and: *Cannabis Therapeutics in HIV/AIDS* (ed: Ethan Russo) Haworth Integrative Healing Press, 103-132.

National Center for Biotechnology Information. (n.d.). PubChem Database. Dronabinol, CID=16078. Retrieved on August 5, 2020 from <https://pubchem.ncbi.nlm.nih.gov/compound/16078>

National Center for Biotechnology Information. (n.d.). PubChem Database. Nabilone, CID=5284592. Retrieved on August 5, 2020 from <https://pubchem.ncbi.nlm.nih.gov/compound/5284592>

National Center for Biotechnology Information. (n.d.). PubChem Database. Nabiximols, CID=44148067. Retrieved August 5, 2020 from <https://pubchem.ncbi.nlm.nih.gov/compound/Nabiximols>

Russo, E.B. (2008). Cannabinoids in the management of difficult to treat pain. *Therapeutics and Clinical Risk Management*, 4(1), 245-259. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/>

Russo, E.B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *British Journal of Pharmacology*, 163(7), 1344-64. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165946/>

Russo, E.B. & Hohmann, A.G. (2013). Role of cannabinoids in pain management. In: *Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches*, 181-197. View abstract: http://link.springer.com/chapter/10.1007%2F978-1-4614-1560-2_18



Section 3: The Whole Plant

Bonn-Miller, M.O., Loflin, M.J.E., Thomas, B.F., Marcu, J.P., Hyke, T., & Vandrey, R. (2017). Labeling accuracy of cannabidiol extracts sold online. *JAMA*, 318(17), 1708–1709. Free online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818782/>

Carlini, B.H., Garrett, S.B., & Carter, G.T. (2017). Medicinal cannabis: a survey among health care providers in Washington State. *American Journal of Hospice & Palliative Care*, 34(1), 85-91. View abstract: <http://dx.doi.org/10.1177/1049909115604669>

Carlini, E.A., Karniol, I.G., Renault, P.F., & Schuster, C.R. (1974). Effects of marijuana in laboratory animals and man. *British Journal of Pharmacology*, 50, 299-309. Free online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1776629/>

Fairbairn, J.W. & Pickens, J.T. (1981). Activity of cannabis in relation to its delta1-trans-tetrahydrocannabinol content. *British Journal of Pharmacology*, 72, 401-9. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2071597>

Hazekamp, A. (2018). The trouble with CBD oil. *Medical Cannabis and Cannabinoids*, 1, 65-72. View abstract: <http://dx.doi.org/10.1159/000489287>

Jikomes, N. & Zoorob, M. (2018). The cannabinoid content of legal cannabis in Washington State varies systematically across testing facilities and popular consumer products. *Scientific Reports* 8, 4519. Free online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852027/>

Kaplan, L., Klein, T., Wilson, M., & Graves, J. (2020). Knowledge, practices, and attitudes of Washington State health care professionals regarding medical cannabis. *Cannabis and Cannabinoid Research*, 5(2), 172-182. View abstract: <https://doi.org/10.1089/can.2019.0051>

Mead, A. (2019). Legal and regulatory issues governing cannabis and cannabis-derived products in the united states. *Frontiers in Plant Science*, 10, 697. Free online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590107/>

Pamplona, F.A., da Silva, L.R., & Coan, A.C. (2018). Potential clinical benefits of cbd-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis [published correction appears in *Frontiers in Neurology*, 2019, 10;9, 1050]. *Frontiers in Neurology*, 9, 759. Free online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143706/>

Russo, E.B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *British Journal of Pharmacology*, 163, 1344-1364. Free online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165946/>

Washington State Department of Agriculture. (n.d.). Hemp CBD in Food. Retrieved August 5, 2020 from <https://agr.wa.gov/departments/food-safety/food-safety/hemp-cbd-in-food>



Section 4: Research on Medicinal Cannabis

Boehnke, K.F., Litinas, E., & Clauw, D.J. (2016). Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. *Journal of Pain*, 17(6), 739-744. View abstract: <http://dx.doi.org/10.1016/j.jpain.2016.03.002>

Dowell, D., Haegerich, T.M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain - United States, 2016 [published correction appears in *MMWR Recommendations and Reports*, 2016, 65(11), 295]. *MMWR Recommendations and Reports*, 65(1), 1-49. Free online: <http://dx.doi.org/10.15585/mmwr.rr6501e1>

Krebs, E.E., Gravelly, A., Nugent, S., Jensen, A.C., DeRonne, B., Goldsmith, E.S., Kroenke, K. Bair, M.J., & Noorbaloochi, S. (2018). Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial. *JAMA*, 319(9), 872-882. View abstract: <http://dx.doi.org/10.1001/jama.2018.0899>

National Academies of Sciences, Engineering, and Medicine. (2017). *The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*. Washington, DC: The National Academies Press. View abstract: <https://doi.org/10.17226/24625>

United States Drug Enforcement Agency. Drug Scheduling. Retrieved on August 5, 2020 from <https://www.dea.gov/drug-scheduling>

Section 5: Legal Aspects of Medicinal Cannabis

Washington State Department of Health. The Cannabis Patient Protection Act. Retrieved on August 5, 2020 from <https://app.leg.wa.gov/RCW/default.aspx?cite=69.51A>